Ischemic tissue microenvironment

The ischemic tissue microenvironment describes the set of pathological changes occurring in tissue after blood flow restriction, such as hypoxia (low oxygen), acidosis (low pH), oxidative stress (high reactive oxygen species), disruption of vascular barriers, heightened inflammation, immune cell infiltration, and extracellular matrix remodeling. These features differ significantly between healthy and ischemic tissue and are dynamic over time. The microenvironment is not a single druggable target but is exploited both for drug delivery (e.g., responsive nanomedicines) and as a context shaping tissue response and therapeutic efficacy. Treatment strategies often aim to modulate or exploit microenvironmental aspects—such as restoring oxygen, dampening harmful inflammation, or supporting tissue repair—to improve outcomes in diseases like stroke and myocardial infarction.

Other names

Ischemic microenvironmentPost-ischemic microenvironmentHypoxic tissue microenvironment

Microenvironment-sensitive drug delivery (responsive to low oxygen, acidosis, ROS, etc.); Anti-inflammatory and anti-fibrotic drug actions (modulate immune cell infiltration, cytokine release); Antioxidant therapy (targeting high ROS); Angiogenic therapy (e.g., VEGF)